Investigational drug · Phase 3
EG-007
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Endometrial Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "EG-007"
First trial start
2026
Aug 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EG-007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Endometrial Cancer
Approved drugs for the same conditions: Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "EG-007" as an intervention, largest first.
- Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial CancerPivotal-lookingNot yet recruiting
Evergreen Therapeutics, Inc.Industry
NCT05077215 · 450 participants (planned) · Start Dec 2026 · Primary completion Dec 2027
Drug: EG-007; Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection and 1 more · For: Advanced Endometrial Cancer
- Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus PemNot yet recruiting
Evergreen Therapeutics, Inc.Industry
NCT05106127 · 28 participants (planned) · Start Aug 2026 · Primary completion Mar 2027
Drug: EG-007; Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection and 1 more · For: Advanced Endometrial Cancer
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Endometrial Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- HB0025Phase 34 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · First-line pMMR Endometrial Cancer, Non Squamous Non-small Cell Lung Cancer, TNBC
- EnvafolimabPhase 24 trials
3D Medicines (Sichuan) Co., Ltd. · Biliary Tract Neoplasms, Solid Tumor, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.